

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 December 2024 (26.12.2024)



(10) International Publication Number
WO 2024/264032 A3

(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/44 (2006.01)
A61K 31/18 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/035216

(22) International Filing Date:

24 June 2024 (24.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/509,699 22 June 2023 (22.06.2023) US

(71) Applicant: **VERALOX THERAPEUTICS INC.**
[US/US]; 321 Ballenger Center Drive, Suite 125, Frederick,
Maryland 21703 (US).

(72) Inventors: **MALONEY, David**; c/o Veralox Therapeu-
tics Inc., 321 Ballenger Center Drive, Suite 125, Freder-
ick, Maryland 21703 (US). **BOXER, Matthew**; c/o Veralox
Therapeutics Inc., 321 Ballenger Center Drive, Suite 125,
Frederick, Maryland 21703 (US).

(74) Agent: **SCHEIDEMAN, Matthew H.** et al.; Cooley LLP,
1299 Pennsylvania Avenue NW, Suite 700, Washington,
District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(88) Date of publication of the international search report:

13 March 2025 (13.03.2025)

(54) Title: COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES

(57) Abstract: The present disclosure provides compounds, compositions, and uses thereof, for example, in the treatment of 12 lipoxy-
genase (12-LOX) mediated diseases.

WO 2024/264032 A3